QualityStocksNewsBreaks – INmune Bio Inc.’s (NASDAQ: INMB) Innovative Drug Candidate Targets Neuroinflammation to Treat Alzheimer’s Disease

INmune Bio (NASDAQ: INMB) is an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, such as Alzheimer’s disease (“AD”). A recent article discussing the company reads, “An association between inflammation and Alzheimer’s disease has long been established. Until present, however, this link and the way in which it could be used to offer reliable AD treatments have both been overlooked. Numerous inflammatory markers are found in AD patients, and several studies establish a link between chronic inflammation and the development of AD. . . . XPro1595 works by targeting the microglial immune cells of the brain. These cells are activated in many AD patients. They cause neuroinflammation that kills nerve cells and promotes synaptic dysfunction. Combined, these two effects lead to dementia in people with AD.”

To view the full article, visit http://ibn.fm/CQDlC

About INmune Bio Inc.

INmune Bio is a publicly traded, clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.INmuneBio.com.

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php